Studying Adolescent Male Sexuality: Where Are We?

This article critically reviews the literature about adolescent males’ sexuality in order to describe the state of the science and to identify promising concepts and research designs that have the potential to guide the next generation of research. A critique was conducted on 94 peer-reviewed studies of sexual behaviors that included a sample of adolescent males; 11 scholarly texts and 2 dissertations. Most studies lacked a theoretical foundation and had cross-sectional designs. For those studies with a theoretical base, 3 perspectives were most often used to guide research: cognitive, biological, or social-environmental. Studies frequently relied on older adolescents or young adult males to report behaviors during early adolescence. Male-only samples were infrequent. Findings include (a) the measurement of sexual activity is frequently limited to coitus and does not explore other forms of “sex”; (b) cognitive factors have been limited to knowledge, attitudes, and intent; (c) little is known about younger males based on their own self-reports; (d) little is known about the normative sexuality development of gay adolescent males; and (e) longitudinal studies did not take into account the complexities of biological, social, and emotional development in interaction with other influences. Research on adolescent sexuality generally is about sexual activity, with little research that includes cognitive competency or young males’ sense of self as a sexual being. The purpose of the paper is to critically review the literature about male sexuality in order to describe the state of the science as well as to identify potential directions to guide the next generation of adolescent male sexual being research.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45299/1/10964_2005_Article_5762.pd

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Rapid changes in carbon and phosphorus after rewetting of dry soil

Drying–rewetting (DRW) cycles are important for soil organic matter turnover; however, few studies have considered the short-term effects on nutrient availability. The pulses in soil respiration, extractable C, P and N pools were quantified after a single DRW cycle (ten sampling times over 49 h). Soil was pre-incubated with or without glucose (2.5 g kg−1) for 10 days to induce differences in the size and activity of the microflora and then either subjected to a single DRW cycle (7-day drying period) or kept constantly moist. A resin extractable P (Presin) method was used and compared to extraction of dissolved organic (DOP) and inorganic P (DIP) with a salt solution. The pulse in soil respiration, extractable organic C (EOC), Presin, DOP and DIP was immediate and greatest in the first 2 h. The Presin pulse was two to three times that measured by solution extraction (DIP). Also, Presin quantified temporal changes in P not apparent in DIP, indicating the advantage of anion-exchange membranes in quantifying short-term changes in P availability. The Presin pulse was smaller in the soil incubated with glucose showing that P pulses will be quantitatively smaller in a soil with an active microbial biomass. In contrast to P, pre-incubation with glucose did not alter EOC concentration or the pulse in EOC after rewetting. The Presin pulse had disappeared by 49 h after DRW despite continued elevated rates of respiration. The sustained increase in DIP following DRW may have implications for plant availability or environmental losses.Clayton R. Butterly, Ann M. McNeill, Jeff A. Baldock and Petra Marschne